New Drugs Acting on Ubiquitin-Proteasome System
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 339
Special Issue Editor
Interests: semisynthetic steroids; diterpenoid and triterpenoid derivatives with improved antitumor activity and investigation of their mechanisms of anticancer action; cancer research; novel PARP-1 inhibitors; enzyme inhibitors able to tackle hormone-dependent cancers, such as 5alpha-reductase and CYP17 inhibitors; new drugs acting on the ubiquitin–proteasome system (UPS); inhibitors of BACE1 and glutaminyl cyclase for Alzheimer’s disease treatment; green pharmaceutical processes
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The controlled regulation of protein turnover is fundamental for the maintenance of cellular homeostasis and viability. The ubiquitin–proteasome system (UPS) is a crucial regulator for the targeted degradation of proteins in eukaryotic cells in diverse cellular processes, such as apoptosis induction, cell cycle control, transcriptional activation, DNA repair, etc. Considering its involvement in a broad spectrum of biological functions, it is not surprising that deregulation of the UPS leads to several different disease states, including various cancers as well as neurodegenerative disorders. UPS comprises a group of enzymes such as E1 (ubiquitin-activating enzymes), E2 (ubiquitin-conjugating enzymes), and E3 (ubiquitin–protein ligases) that tag proteins with the small-molecule ubiquitin (Ub), and the multi-subunit proteolytic complex, the 26S proteasome, a highly specific molecular device that degrades Ub-tagged substrate proteins into small molecular peptides involved in other biological functions. Deubiquitinases (DUBs) regulate biological processes associated with cell proliferation and apoptosis and are components of the UPS that catalyze the removal of ubiquitin moieties from target proteins or polyubiquitin chains, resulting in altered signaling or changes in protein stability. Ubiquitin-specific proteases (USPs) are the largest subfamily of DUBs. This Special Issue aims to provide an opportunity to share new findings and recent advances in UPS-targeted small molecules toward the development of new anticancer drugs.
Prof. Dr. Jorge A. R. Salvador
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Proteasome inhibitors
- Ubiquitin-activating enzymes inhibitors
- Ubiquitin-conjugating enzymes inhibitors
- Ubiquitin–protein ligases inhibitors
- Ubiquitin-specific proteases (USPs) inhibitors
- Other deubiquitinases inhibitors
